Metabolically obese normal weight individuals: An intriguing phenotype;Sujets «métaboliquement obèses» sans excès de poids: Un phénotype interpellant

Revue Medicale de Liege

Volumn 64, Issue 1, 2009, Pages 14-22

  Beck, E ^a   Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular risk; Metabolic syndrome; Metabolically obese normal weight; Obesity; Type 2 diabetes; Visceral adipose tissue

Indexed keywords

ADIPONECTIN; ANDROGEN; FATTY ACID; GLITAZONE DERIVATIVE; GLUCOCORTICOID RECEPTOR; GLUCOSE; INSULIN; LEPTIN; METFORMIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOCHEMISTRY; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIET; DISEASE ASSOCIATION; FAMILY HISTORY; GLUCOGENESIS; HORMONE SYNTHESIS; HUMAN; HYPERADRENOCORTICISM; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; LIPID STORAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PHYSICAL ACTIVITY; PROGNOSIS; RISK FACTOR; SCORING SYSTEM; SKELETAL MUSCLE; TOBACCO DEPENDENCE; WEIGHT REDUCTION;

EID: 59649083487     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Van Gaal LF, Mertens IL, De Block CE. - Mechanisms linking obesity with cardiovascular disease. Nature, 2006, 444, 875-880.
2. Després JP, Lemieux I, Bergeron J, et al. - Abdominal obesity and the metabolic syndrome : contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol, 2008, 28, 1039-1049.
3. Scheen AJ, Luyckx FH, Lefèbvre PJ. - Comment j'explore... Le syndrome métabolique par sa nouvelle définition dite de «consensus». Rev Med Liège, 2006, 61, 48-52.
4. Scheen AJ. - Le syndrome métabolique : physiopathologie et traitement. In : Athérosclérose Athérothrombose (Eds : Kulbertus H., Van Mieghem W.), Transmed Medical Communications, Lubbeek, Belgium, 2006, 161-190.
5. St-Onge MP, Janssen I, Heymsfield SB. - Metabolic syndrome in normal-weight Americans : new definition of the metabolically obese, normal-weight individual. Diabetes Care, 2004, 24, 2222-2228.
6. Ruderman NB, Schneider SH, Berchtold P. - The «metabolically-obese, » normal-weight individual. Am J Clin Nutr, 1981, 34, 1617-1621.
7. Ruderman NB, Berchtold P, Schneider S. - Obesity-associated disorders in normal-weight individuals: some speculations. Int J Obes, 1982, 6 (Suppl 1), 151-157.
8. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. - The metabolically obese, normal-weight individual revisited. Diabetes, 1998, 47, 699-713.
9. Conus F, Rabasa-Lhoret R, Peronnet F. - Characteristics of metabolically obese normal-weight (MONW) subjects. Appl Physiol Nutr Metab, 2007, 32, 4-12.
10. Scheen AJ. - Evaluation de l'insulinosécrétion et de l'insulinosensibilité chez l'homme. Thérapie, 2007, 62, 311-318.
11. Ferrannini E, Natali A, Bell P, et al. - Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest, 1997, 100, 1166-1173.
12. The DECODE Study Group. - Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk? Int J Obesity, 2008, 32, 757-762.
13. McLaughlin T, Allison G, Abbasi F, et al. - Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism, 2004, 53, 495-499.
14. Ryan MC, Fernster Farin HM, Abbasi F, Reaven GM. - Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease. Am J Cardiol, 2008, 102, 40-46.
15. Park YW, Zhu S, Palaniappan L et al. - The metabolic syndrome : prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med, 2003, 163, 427-436.
16. Widman RP, Muntner P, Reynolds K, et al. - The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering. Prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med, 2008, 168, 1617-1624.
17. Pannier B, Thomas F, Eschwège E, et al. - Cardiovascular risk markers associated with the metabolic syndrome in a large French population : the SYMFONIE study. Diabetes Metab, 2006, 32, 467-474.
18. Rietzschel ER, De Buyzere ML, Bekaert S, et al. - Rationale, design, methods and baseline characteristics of the Asklepios Study. Eur J Cardiovasc Prev Rehabil, 2007, 14, 179-191.
19. Klein S, Allison DB, Heymsfield SB, et al. - Waist circumference and cardiometabolic risk : a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; The American Society for Nutrition; and the American Diabetes Association. Diabetes Care, 2007, 30, 1647-1652.
20. Colditz GA, Willett WC, Rotnitzky A, Manson JE. - Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med, 1995, 122, 481-486.
21. Conus F, Allison DB, Rabasa-Lhoret R, et al. - Metabolic and behavioral characteristics of metabolically obese but normal-weight women. J Clin Endocrinol Metab, 2004, 89, 5013-5020.
22. Balkau B, Mhamdi L, Oppert JM, et al. - Physical activity and insulin sensitivity. The RISC Study. Diabetes, 2008, Jun 30, sous presse.
23. Scheen AJ, Paquot N. - Effets bénéfiques de l'activité physique sur les facteurs de risque cardio-vasculaire. Rev Med Liège, 2001, 56, 239-243.
24. Hyun YJ, Koh SJ, Chae JS, et al. - Atherogenecity of LDL and unfavorable adipokine profile in metabolically obese, normal-weight woman. Obesity, 2008, 16, 784-789.
25. Freedland ES. - Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab (Lond), 2004, 1, 12
26. Magis D, Geronooz I, Scheen AJ. - Tabagisme, insulinorésistance et diabète de type 2. Rev Med Liège, 2002, 57, 575-581.
27. Chiolero A, Faeh D, Paccaud F, Cornuz J. - Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr, 2008, 87, 801-809.
28. Prentice AM, Rayco-Solon P, Moore SE. - Insights from the developing world : thrifty genotypes and thrifty phenotypes. Proc Nutr Soc, 2005, 64, 153-161.
29. De Lorenzo A, Martinoli R, Vaia F, Di Renzo L. - Normal weight obese (NWO) women: an evaluation of a candidate new syndrome. Nutr Metab Cardiovasc Dis, 2006, 16, 513-523.
30. Di Renzo L, Del Gobbo V, Bigioni M, et al. - Body composition analyses in normal weight obese women. Eur Rev Med Pharmacol Sci, 2006, 10, 191-196.
31. Katsuki A, Urakawa H, Gabazza EC, et al. - Quantitative insulin sensitivity check index is a useful indicator of insulin resistance in Japanese metabolically obese, normal-weight subjects with normal glucose tolerance. Endocr J, 2005, 52, 253-257.
32. Katsuki A, Sumida Y, Urakawa H, et al. - Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care, 2003, 26, 2341-2344
33. Luyckx FH, Scheen AJ. - Comment j'explore... les anomalies du métabolisme glucidique, de l'insulinosécrétion et de la sensibilité à l'insuline avec une hyperglycémie provoquée par voie orale. Rev Med Liège, 2001, 55, 881-885.
34. Abbasi F, Chu JW, Malendola C, et al. - Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes, 2004, 53, 585-590.
35. Katsuki A, Sumida Y, Urakawa H, et al. - Plasma levels of adiponectin are associated with insulin resistance and serum levels of triglyceride in Japanese metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Care, 2003, 26, 2964-2965.
36. Katsuki A, Suematsu M, Gabazza EC, et al. - Decreased high-molecular weight adiponectin-to-total adiponectin ratio in sera is associated with insulin resistance in Japanese metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Care, 2006, 29, 2327-2328.
37. Fox CS, Massaro JM, Hoffmann U, et al. - Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation, 2007, 116, 39-48.
38. Yki-Järvinen H. - Fat in the liver and insulin resistance. Ann Med, 2005, 37, 347-356.
39. Moro C, Bajpeyi S, Smith SR. - Determinants of intramyocellular triglyceride turnover: implications for insulin sensitivity. Am J Physiol Endocrinol Metab, 2008, 294, E203-213.
40. Di Renzo L, Bigioni M, Bottini FG, et al. - Normal weight obese syndrome: role of single nucleotide polymorphism of IL-1 5Ralpha and MTHFR 677C - >T genes in the relationship between body composition and resting metabolic rate. Eur Rev Med Pharmacol Sci, 2006, 10, 235-245.
41. Lihn AS, Pedersen SB, Richelsen B.- Adiponectin: Action, regulation and association to insulin sensitivity. Obes Rev, 2005, 6, 13-21.
42. Walker BR, Andrew R. - Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann N Y Acad Sci, 2006, 1083, 165-184.
43. Paterson JM, Morton NM, Fievet C, et al. - Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A, 2004, 101, 7088-7093.
44. Chubb SA, Hyde Z, Almeida OP, et al. - Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men : the Health in Men Study. Eur J Endocrinol, 2008, 158, 785-792.
45. Phillips GB, Jing T, Heymsfield SB. - Does insulin resistance, visceral adiposity, or a sex hormone alteration underlie the metabolic syndrome ? Studies in women. Metabol Clin Exp, 2008, 57, 838-844.
46. Succurro E, Marini MA, Frontoni S, et al. - Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. Obesity, 2008, June 12 [Epub ahead of print].
47. Katsuki A, Suematsu M, Gabazza EC, et al. - Increased oxidative stress is associated with decreased circulating levels of adiponectin in Japanese metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Res Clin Pract, 2006, 73, 310-314.
48. Balkau B, Deanfield JE, Després JP, et al. - International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation, 2007, 116, 1942-1951.
49. Yusuf S, Hawken S, Ounpuu S, et al. - Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet, 2005, 366, 1640-1649.
50. Scheen AJ. - Management of the metabolic syndrome. Minerva Endocrinol, 2004, 29, 31-45.
51. Lindström J, Ilanne-Parikka P, Peltonen M, et al. - Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet, 2006, 368, 1673-1679.
52. Rucker D, Padwal R, Li SK, et al. - Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ, 2007, 335, 1194-1199.
53. Scheen AJ. - The future of obesity: new drugs versus lifestyle interventions ? (Editorial). Exp Opin Invest Drugs, 2008, 17, 263-267.
54. Dvorak RV, DeNino WF, Ades PA, Poehlman ET. - Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes, 1999, 48, 2210-2214.
55. Fontbonne A, Charles MA, Juhan-Vague I, BIGPRO Study Group. - The effect of metformin on the metabolic abnormalities associated with upper body fat distribution. Diabetes Care, 1994, 19, 920-926.
56. Miyazaki Y, Mahankali A, Matsuda M, et al. - Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab, 2002, 87, 2784-2791.